Erratum: The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells (International Journal of Oncology (2015) 46 (1924-1934) DOI: 10.3892/ijo.2015.2931);The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells

International Journal of Oncology

Volumn 46, Issue 5, 2015, Pages 1924-1934

  Wang, Yifei ^a   Han, Alex ^b   Chen, Eva ^b   Singh, Rakesh K ^b   Chichester, Clinton O ^c   Moore, Richard G ^b   Singh, Ajay P ^a   Vorsa, Nicholi ^a,d  

^a RUTGERS UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Apoptosis; Cell cycle; Cranberry; Flavonoids; Ovarian cancer

Indexed keywords

CASPASE 3; CISPLATIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVONOID; HISTONE H3; PAC DP 9; PROTEIN P21; QUERCETIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTIOXIDANT; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROANTHOCYANIDIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL VIABILITY; CHEMOSENSITIVITY; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CRANBERRY; DNA REPAIR; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG PURIFICATION; DRUG SCREENING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IC50; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MTS ASSAY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; CELL CYCLE CHECKPOINT; CELL SURVIVAL; CHEMISTRY; CHROMATOGRAPHY; DNA FRAGMENTATION; DRUG EFFECTS; DRUG POTENTIATION; INDIRECT FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL CULTURE; TUNEL ASSAY;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL SURVIVAL; CHROMATOGRAPHY; CISPLATIN; DNA FRAGMENTATION; DRUG SYNERGISM; EPIDERMAL GROWTH FACTOR; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IN SITU NICK-END LABELING; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROANTHOCYANIDINS; QUERCETIN; TUMOR CELLS, CULTURED; VACCINIUM MACROCARPON;

EID: 84925445605     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2022.5408     Document Type: Erratum

References (36)

1. Jacobs IJ and Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3: 355-366, 2004.
2. Agarwal R and Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516, 2003.
3. American Cancer Society: Ovarian Cancer Key Statistics (http://www.cancer.org/cancer/ovariancancer/index), 2014.
4. Foo LY, Lu Y, Howell AB and Vorsa N: A-Type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli. J Nat Prod 63: 1225-1228, 2000.
5. Seeram NP, Adams LS, Hardy ML and Heber D: Total cranberry extract versus its phytochemical constituents: Antiproliferative and synergistic effects against human tumor cell lines. J Agric Food Chem 52: 2512-2517, 2004.
6. Neto CC: Cranberry and its phytochemicals: A review of in vitro anticancer studies. J Nutr 137 (Suppl): S186-S193, 2007.
7. Neto CC, Krueger CG, Lamoureaux TL, et al: MALDI-TOFMS characterization of proanthocyanidins from cranberry fruit (Vaccinium macrocarpon) that inhibit tumor cell growth and matrix metalloproteinase expression in vitro. J Sci Food Agric 86: 18-25, 2006.
8. Ferguson PJ, Kurowska E, Freeman DJ, Chambers AF and Koropatnick DJ: A flavonoid fraction from cranberry extract inhibits proliferation of human tumor cell lines. J Nutr 134: 1529-1535, 2004.
9. Singh AP, Singh RK, Kim KK, Satyan KS, Nussbaum R, Torres M, Brard L and Vorsa N: Cranberry proanthocyanidins are cytotoxic to human cancer cells and sensitize platinum-resistant ovarian cancer cells to paraplatin. Phytother Res 23: 1066-1074, 2009.
10. Kim KK, Singh AP, Singh RK, Demartino A, Brard L, Vorsa N, Lange TS and Moore RG: Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells. Int J Oncol 40: 227-235, 2012.
11. Singh AP, Lange TS, Kim KK, Brard L, Horan T, Moore RG, Vorsa N and Singh RK: Purified cranberry proanthocyanidines (PAC-1A) cause pro-apoptotic signaling, ROS generation, cyclophosphamide retention and cytotoxicity in high-risk neuroblastoma cells. Int J Oncol 40: 99-108, 2012.
12. Vvedenskaya IO, Rosen RT, Guido JE, Russell DJ, Mills KA and Vorsa N: Characterization of flavonols in cranberry (Vaccinium macrocarpon) powder. J Agric Food Chem 52: 188-195, 2004.
13. Wilson T, Singh AP, Vorsa N, Goettl CD, Kittleson KM, Roe CM, Kastello GM and Ragsdale FR: Human glycemic response and phenolic content of unsweetened cranberry juice. J Med Food 11: 46-54, 2008.
14. Singh AP, Wilson T, Kalk AJ, Cheong J and Vorsa N: Isolation of specific cranberry flavonoids for biological activity assessment. Food Chem 116: 963-968, 2009.
15. Nicholson RI, Gee JMW and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37 (Suppl 4): S9-S15, 2001.
16. Schilder RJ, Hall L, Monks A, Handel LM, Fornace AJ Jr, Ozols RF, Fojo AT and Hamilton TC: Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 45: 416-422, 1990.
17. Bacchetti S and Graham F: Inhibition of cell-proliferation by an adenovirus vector expressing the human wild type-p53 protein. Int J Oncol 3: 781-788, 1993.
18. Anderson NG, Ahmad T, Chan K, Dobson R and Bundred NJ: ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 94: 774-782, 2001.
19. Shen SC, Chen YC, Hsu FL and Lee WR: Differential apoptosis-inducing effect of quercetin and its glycosides in human promyeloleukemic HL-60 cells by alternative activation of the caspase 3 cascade. J Cell Biochem 89: 1044-1055, 2003.
20. Murota K, Shimizu S, Chujo H, Moon JH and Terao J: Efficiency of absorption and metabolic conversion of quercetin and its glucosides in human intestinal cell line Caco-2. Arch Biochem Biophys 384: 391-397, 2000.
21. Yarden Y: The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 (Suppl 4): S3-S8, 2001.
22. Sun Q, Prasad R, Rosenthal E and Katiyar SK: Grape seed proanthocyanidins inhibit the invasiveness of human HNSCC cells by targeting EGFR and reversing the epithelial-to-mesenchymal transition. PLoS One 7: e31093-e31093, 2012.
23. Rodemann HP, Dittmann K and Toulany M: Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol 83: 781-791, 2007.
24. Wang SC and Hung MC: Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res 15: 6484-6489, 2009.
25. Liccardi G, Hartley JA and Hochhauser D: EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res 71: 1103-1114, 2011.
26. Jamieson ER and Lippard SJ: Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99: 2467-2498, 1999.
27. Jung Y and Lippard SJ: Direct cellular responses to platinum-induced DNA damage. Chem Rev 107: 1387-1407, 2007.
28. Stokoe D, Macdonald SG, Cadwallader K, Symons M and Hancock JF: Activation of Raf as a result of recruitment to the plasma membrane. Science 264: 1463-1467, 1994.
29. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
30. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R and McCubrey JA: Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol 22: 469-480, 2003.
31. Hans F and Dimitrov S: Histone H3 phosphorylation and cell division. Oncogene 20: 3021-3027, 2001.
32. Chadee DN, Hendzel MJ, Tylipski CP, Allis CD, Bazett-Jones DP, Wright JA and Davie JR: Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. J Biol Chem 274: 24914-24920, 1999.
33. Agarwal ML, Agarwal A, Taylor WR and Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92: 8493-8497, 1995.
34. WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells. Mol Cancer 4: 41-41, 2005.
35. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
36. Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-149, 2003.